Reimbursed Care Access in Heard Island and McDonald Islands

Detailed medical-access context: In Australia (and therefore applying to Heard Island and McDonald Islands by virtue of Australian jurisdiction), psilocybin was moved from Schedule 9 to Schedule 8 in the Poisons Standard for a restricted medical use — specifically for treatment‑resistant depression (TRD) when prescribed by an authorised psychiatrist under the TGA Authorised Prescriber scheme. Access requires psychiatrist authorisation, compliance with strict importation/manufacturing controls, and adherence to state/territory implementing legislation and monitoring; supplies remain highly regulated and no general retail or recreational supply is permitted. The Therapeutic Goods Administration (TGA) published an update describing that from 1 July 2023 authorised psychiatrists may prescribe psilocybin for TRD, but that psilocybin remains Schedule 9 for other indications and that importation/supply and training/clinic readiness are tightly controlled. There are currently no broadly ARTG-registered, publicly reimbursed psilocybin products listed for general prescribing; state/territory adoption of Poisons Standard controls and local prescribing pathways (Authorised Prescriber approvals, HREC considerations) must also be satisfied before clinical use. # #.

Detailed medical-access context: MDMA was rescheduled by the TGA so that, for a limited, specified indication, authorised psychiatrists may prescribe MDMA for the treatment of post‑traumatic stress disorder (PTSD) under the Authorised Prescriber framework. This is a restricted pathway: prescribing must be by psychiatrists authorised under TGA processes, supply and importation are subject to special licences and state/territory controls, and MDMA remains Schedule 9 for all other indications. There are no widely available ARTG-registered MDMA products for general prescribing and routine reimbursement is not available — access is through authorised prescriber approvals or clinical trials, and substantial regulatory and clinic safeguards (supply/import licences, certified facilities, clinician training) apply. The TGA Q&A and the 1 July 2023 update explain the limitation to PTSD and the continuing Schedule 9 status for other uses. # #.

Deep medical and reimbursement context: Esketamine (Spravato®) is an ARTG-registered medicine in Australia (TGA decision date 5 March 2021; ARTG entry SPRAVATO ARTG ID 311827) and is specifically indicated for treatment‑resistant depression in adults, to be initiated with an oral antidepressant. Spravato is a Schedule 8 (controlled) medicine and must be administered in a supervised clinical setting with monitoring due to risk of dissociation and blood‑pressure effects. As of 1 May 2025 Spravato was made subsidised under the Pharmaceutical Benefits Scheme (PBS) for eligible patients with TRD (government PBS listing announcements and contemporary clinical communications describe eligibility criteria tied to prior antidepressant trial failures and specialist prescribing pathways). Even with PBS subsidy, administration requires certified clinics and monitoring, and patients commonly face clinic professional fees in addition to any medicine co‑payment. State/territory authorisations and clinic accreditation processes (including the requirement for supervised dosing and observation periods) remain in place; prescribing is constrained to appropriately credentialed clinicians and treatment centres. For formal regulatory and product registration details, see the TGA Spravato product pages and ARTG listing. # # #.

Deep medical context (concise): Injectable and generic racemic ketamine are registered in Australia primarily as anaesthetic agents; use of ketamine (injectable or off‑label preparations) for depression (including TRD) is commonly practised in specialist clinics and research settings but remains off‑label — i.e., not TGA‑approved for depression. Off‑label ketamine infusions are frequently delivered in private clinics under state/territory Schedule 8 controls; clinicians must comply with local controlled‑drug authorisation processes (which vary by state/territory), and routine public reimbursement (Medicare/PBS) for off‑label ketamine for psychiatric indications is generally unavailable. State health guidance (e.g., NSW) requires approvals or notifications for prescribing ketamine for TRD in many circumstances and directs that administration occur in medically equipped settings with monitoring. The Royal Australian and New Zealand College of Psychiatrists and other specialist bodies recommend governance and oversight when using ketamine off‑label for mental health indications. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (and preparations containing DMT such as traditional ayahuasca brews) are captured as prohibited Schedule 9 substances under the Australian Poisons Standard and require special licences/approvals for authorised research or clinical trials; recreational manufacture, possession, importation or supply is unlawful. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is treated in Australia as a prohibited/substantially controlled tryptamine (Schedule 9 in the Poisons Standard context) and may only be used lawfully within authorised research frameworks with the necessary federal and state approvals. Enforcement and penalties for possession or supply outside permitted channels apply under Australian criminal and medicines regulation. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not an approved therapeutic medicine in Australia and possession, supply or import without specific licences/approvals is prohibited; any medical research requires explicit TGA/state approvals and ethics committee review. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ayahuasca preparations (which contain DMT and MAOI-containing plant materials) are illegal to possess, import, or supply in Australia except under tightly controlled research exemptions and licences. There is no authorised religious or ceremonial exemption available equivalent to some other jurisdictions; lawful use requires explicit regulatory approvals. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline is included in the prohibited substance framework (Schedule 9) under Australian drug/poisons scheduling and cannot be manufactured, possessed, or supplied except under authorised research licences and approvals. Note that plant species containing mescaline (e.g., some cacti) are also regulated and subject to importation/possession controls. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The synthetic phenethylamine family (2C‑series) is prohibited under Australian scheduling and criminal law; any possession, manufacture, importation or supply outside approved research channels is unlawful and subject to enforcement. #.